

16th February 16:00–17:30

Biopharma CxO Roundtable

Clinical trial acceleration — 500 days faster from start to finish

On behalf of McKinsey & Company and Hadean Ventures, it is our pleasure to invite you to our inaugural Biopharma CxO Roundtable

For this roundtable, we will focus on a key question for Norway's biopharmas: How can we accelerate clinical trials, and thereby get drugs to market faster?

McKinsey's experts in Clinical Development Excellence will be holding a presentation on the levers that can be deployed to achieve a 500 day reduction in time from start to finish of clinical trials.

Kind regards,
Frithjof Lund, Karsten Dalgaard, and Ingrid Teigland Akay

In addition to sharing our latest thinking with you, we would also like to create a forum for Norway's biopharma leaders to share their expertise with each other. Panelists from several of Norway's most exciting companies will be joining to discuss their experiences and perspectives on clinical trials.

The meeting will be held virtually.

Please register [here](#) before the 12th of February

We hope to see you there.

McKinsey
& Company



PANELISTS

Michael Engsig

CEO, Vaccibody



Torbjørn Furuseth

CFO, Targovax



Jostein Dahle

CSO, Nordic Nanovector



Jan Alfheim

CEO, Oncoinvent



Kostas Alevizopoulos

CEO, APIM Therapeutics



Per Walday

CEO, PCI Biotech



Lena Nymo Helli

CEO, Norway Health Tech

